ADAM8

Across TCGA pan-cancer cohorts, ADAM8 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ADAM8 data layer compared with 25 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher ADAM8 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated ADAM8 expression acts as an unfavorable survival marker, although some lineages such as HNSC show a favorable association.

PDAC, LUAD, and LSCC are the cancer types where ADAM8 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Tertile	All	0.770	0.983	<.001	56	view →
LUAD	OS	Quartile	II,III,IV	0.261	0.643	.006	19	view →
LSCC	OS	Quartile	II,III,IV	0.583	1.000	.014	10	view →
COAD	DFS	Median	III,IV	0.614	1.000	.038	6	view →
HNSC	OS	Median	III,IV	1.000	0.349	.040	4	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ADAM8–PDAC (OS)

Open the PDAC breakdown →